The Role of p53-R249S’s GOF in HCC development
The Role of p53-R249S’s GOF in HCC development
批准号:
10543734
负责人:
Hua Lu
金额:
$35.4万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2024-12-31
关键词:
AddressAflatoxin B1AreaAsiaAutomobile DrivingBindingBiochemicalBiogenesisBiologicalCDK4 geneCell CycleCell Cycle ProgressionCell NucleusCell ProliferationCell SurvivalCellsCentral AfricaChinaClinical TrialsCombined Modality TherapyCyclin D1DevelopmentDiagnosisDisseminated Malignant NeoplasmDominant-Negative MutationDrug resistanceExposure toFBXW7 geneFutureGene ExpressionGenesGeneticGenetic TranscriptionGenomicsGoalsGrowthHBV and AflatoxinHepatitis B InfectionHepatitis B VirusHot SpotHumanInvadedKnock-inKnock-in MouseKnowledgeLightLinkLiverMalignant Epithelial CellMalignant NeoplasmsManuscriptsMediatingMolecularMolecular TargetMusMutateMutationNIMANuclearNuclear ImportOncogenicOncoproteinsPathway interactionsPatientsPeptidylprolyl IsomerasePhosphorylationPhosphotransferasesPlayPrimary carcinoma of the liver cellsProliferatingProtein BiosynthesisPublishingResearchRibosomesRoleSequence AnalysisSignal PathwayTP53 geneTestingTranscriptTumor Suppressor Genesc-myc Genescancer cellcancer stem cellcancer therapycell growthcis-trans-Isomerasescohortcombinatorialdesigndietaryexposed human populationgain of functioninsightloss of functionmutantprogramsrational designstem cell divisiontranscription factortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
This application is proposed to determine the biological role of a specific p53 mutant, R249S (p53-RS), whose
Arg 249 is substituted by Ser, in development and progression of hepatocellular carcinoma (HCC) and to
divulge molecular mechanisms underlying its gain of function (GOF) crucial for its oncogenic role. Remarkably,
p53-RS is highly associated with HCC patients who are often exposed to dietary aflatoxin B1 (AFB1) and
infected with Hepatitis Virus B (HBV) in Asia and central Africa, as it is the only hotspot p53 mutation identified
among HCC patients. Since genetic knockin of mouse R246S (equivalent to human R249S) without any
oncogenic challenges only showed its loss of function (LOF) and dominant negative (DN) effect on cancer
development without any GOF activity, it has still remained elusive if p53-RS possesses GOF activity important
for proliferation, invasion and tumorigenesis of HCC. If so, what would be the underlying mechanism for this
GOF activity. Our recent studies uncovered the unique link of a cell cycle-regulated kinase, CDK4, Cyclin
D1(CycD1), a peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1), and an oncoprotein c-Myc with the
GOF activity of p53-RS. All of these four oncoproteins, CDK4, CycD1, PIN1, and c-Myc play critical roles in the
cell cycle progression and cancer cell proliferation and growth, and are highly expressed in various types of
human cancers, including HCC. Our preliminary and published studies showed that CDK4/CycD1 can
specifically bind to and phosphorylate p53-RS at its HCC-derived Ser249, and this phosphorylation facilitates
p53-RS's PIN1 binding and subsequent nuclear localization. In the nucleus, p53-RS binds to and stabilizes c-
Myc by blocking FBW7-mediated degradation, consequently leading to c-Myc activation and increase of
synthesis of ribosomal proteins-encoded transcripts. Through these actions, p53-RS executes its GOFs activity
crucial for HCC cell proliferation and survival. In light of our preliminary results, we hypothesize a unique
mechanism for this p53 mutant's GOF, i.e., substitution of Arg249 with Ser renders this mutant to a new
phospohorylation substrate for CDK4/CycD1 during the cell cycle, and phosphorylation at this residue makes
p53-RS more accessible for PIN1-binding; As a result, PIN1 facilitates the transport of this mutant p53 to the
nucleus where it promotes HCC proliferation by binding to and activating c-Myc, promoting HCC development
and progression. We will test this hypothesis by addressing two specific aims: 1) To further decipher
biochemical mechanisms underlying the GOF of p53-RS in HCC; 2) To determine if p53-RS's GOF plays
a role in HBV-associated HCC development. Completing these comprehensive studies would gain critical
information for our better understanding of the unique signaling pathway underlying p53-RS's GOF in HCC
development and progression, and also unveil CDK4/CycD1, PIN1 and c-Myc as molecular targets for
developing a more effective combinatorial therapy for HCCs that harbor p53-RS.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bbrc.2020.01.152
发表时间:
2020-04-09
期刊:
Biochemical and biophysical research communications
影响因子:
3.1
作者:
[Liao P, Bhattarai N, Cao B, Zhou X, Jung JH, Damera K, Fuselier TT, Thareja S, Wimley WC, Wang B, Zeng SX, Lu H]
通讯作者:
Lu H
DOI:
10.1016/j.pccm.2023.07.001
发表时间:
2023-09
期刊:
Chinese medical journal pulmonary and critical care medicine
影响因子:
--
作者:
[Wallbillich, Nicholas J, Lu, Hua]
通讯作者:
Lu, Hua
Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy
-
批准号:10492834
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2022
-
负责人:Hua Lu
-
依托单位:
Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy
-
批准号:10671541
-
项目类别:
-
资助金额:$21.03万
-
财政年份:2022
-
负责人:Hua Lu
-
依托单位:
Digital Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples
-
批准号:10037327
-
项目类别:
-
资助金额:$63.1万
-
财政年份:2020
-
负责人:Hua Lu
-
依托单位:
The Role of p53-R249S’s GOF in HCC development
-
批准号:10317044
-
项目类别:
-
资助金额:$35.16万
-
财政年份:2019
-
负责人:Hua Lu
-
依托单位:
Role of the AMPK-MDMX-p53 pathway in cancer
-
批准号:9753938
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2019
-
负责人:Hua Lu
-
依托单位:
Targeting GRP78 for p53 activation as anti-cancer therapy
-
批准号:9008031
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2015
-
负责人:Hua Lu
-
依托单位:
The Eighth International Mdm2 Workshop
-
批准号:9022188
-
项目类别:
-
资助金额:$0.78万
-
财政年份:2015
-
负责人:Hua Lu
-
依托单位:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
-
批准号:9102015
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2012
-
负责人:Hua Lu
-
依托单位:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
-
批准号:8551655
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2012
-
负责人:Hua Lu
-
依托单位:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
-
批准号:8421099
-
项目类别:
-
资助金额:$29.41万
-
财政年份:2012
-
负责人:Hua Lu
-
依托单位:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
-
批准号:8717615
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2012
-
负责人:Hua Lu
-
依托单位:
Role of ribosomal proteins in regulating c-Myc
-
批准号:7805570
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2008
-
负责人:Hua Lu
-
依托单位:
Role of ribosomal proteins in regulating c-Myc
-
批准号:8068673
-
项目类别:
-
资助金额:$30.39万
-
财政年份:2008
-
负责人:Hua Lu
-
依托单位:
Role of ribosomal proteins in regulating c-Myc
-
批准号:8247175
-
项目类别:
-
资助金额:$30.29万
-
财政年份:2008
-
负责人:Hua Lu
-
依托单位:
Role of ribosomal proteins in regulating c-Myc
-
批准号:7522668
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2008
-
负责人:Hua Lu
-
依托单位:
Role of ribosomal proteins in regulating c-Myc
-
批准号:7643954
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2008
-
负责人:Hua Lu
-
依托单位:
Role of the AMPK-MDMX-p53 pathway in cancer
-
批准号:8963004
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2007
-
负责人:Hua Lu
-
依托单位:
Role of the AMPK-MDMX-p53 pathway in cancer
-
批准号:9333196
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2007
-
负责人:Hua Lu
-
依托单位:
Interplay between 14-3-3gamma and MDMX in regulating the p53 pathway
-
批准号:7890608
-
项目类别:
-
资助金额:$28.38万
-
财政年份:2007
-
负责人:Hua Lu
-
依托单位:
Interplay between 14-3-3gamma and MDMX in regulating the p53 pathway
-
批准号:7386981
-
项目类别:
-
资助金额:$28.49万
-
财政年份:2007
-
负责人:Hua Lu
-
依托单位:
海外基金